|
1
|
Crombie JL and Armand P: Diffuse large
B-cell lymphoma and high-grade B-cell lymphoma: Genetic
classification and its implications for prognosis and treatment.
Hematol Oncol Clin North Am. 33:575–585. 2019. View Article : Google Scholar
|
|
2
|
International Non-Hodgkins Lymphoma
Prognostic Factors Project: A predictive model for aggressive
non-Hodgkins lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar
|
|
3
|
Vaidya R and Witzig TE: Prognostic factors
for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol.
25:2124–2133. 2014. View Article : Google Scholar
|
|
4
|
Sampedro F, Domenech A and Escalera S:
Obtaining quantitative global tumoral state indicators based on
whole-body PET/CT scans: A breast cancer case study. Nucl Med
Commun. 35:362–371. 2014. View Article : Google Scholar
|
|
5
|
Park S, Moon SH, Park LC, Hwang DW, Ji JH,
Maeng CH, Cho SH, Ahn HK, Lee JY, Kim SJ, et al: The impact of
baseline and interim PET/CT parameters on clinical outcome in
patients with diffuse large B cell lymphoma. Am J Hematol.
87:937–940. 2012. View Article : Google Scholar
|
|
6
|
Koff JL and Flowers CR: Prognostic
modeling in diffuse large B-cell lymphoma in the era of
immunochemotherapy: Where do we go from here? Cancer.
123:3222–3225. 2017. View Article : Google Scholar
|
|
7
|
Reddy A, Zhang J, Davis NS, Moffitt AB,
Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L,
Karjalainen-Lindsberg ML, et al: Genetic and functional drivers of
diffuse large B cell lymphoma. Cell. 171:481–494.e15. 2017.
View Article : Google Scholar
|
|
8
|
Islam P, Goldstein J and Flowers CR:
PET-derived tumor metrics predict DLBCL response and
progression-free survival. Leuk Lymphoma. 60:1965–1971. 2019.
View Article : Google Scholar
|
|
9
|
Cottereau AS, Lanic H, Mareschal S,
Meignan M, Vera P, Tilly H, Jardin F and Becker S: Molecular
profile and FDG-PET/CT total metabolic tumor volume improve risk
classification at diagnosis for patients with diffuse large B-cell
lymphoma. Clin Cancer Res. 22:3801–3809. 2016. View Article : Google Scholar
|
|
10
|
Barrington SF, Mikhaeel NG, Kostakoglu L,
Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher
RI, Trotman J, et al: Role of imaging in the staging and response
assessment of lymphoma: Consensus of the international conference
on malignant lymphomas imaging working group. J Clin Oncol.
32:3048–3058. 2014. View Article : Google Scholar
|
|
11
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia and Lymphoma Group and Eastern Cooperative Oncology
Group; European Mantle Cell Lymphoma Consortium, ; et al:
Recommendations for initial evaluation, staging, and response
assessment Hodgkin and non-Hodgkin lymphoma: The Lugano
classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar
|
|
12
|
Mikhaeel NG, Smith D, Dunn JT, Phillips M,
Møller H, Fields PA, Wrench D and Barrington SF: Combination of
baseline metabolic tumour volume and early response on PET/CT
improves progression-free survival prediction in DLBCL. Eur J Nucl
Med Mol Imaging. 43:1209–1219. 2016. View Article : Google Scholar
|
|
13
|
Zhang YY, Song L, Zhao MX and Hu K: A
better prediction of progression-free survival in diffuse large
B-cell lymphoma by a prognostic model consisting of baseline TLG
and %ΔSUVmax. Cancer Med. 5:5137–5147. 2019. View Article : Google Scholar
|
|
14
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised international prognostic index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar
|
|
15
|
Zhou Z, Sehn LH, Rademaker AW, Gordon LI,
Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA,
Rodriguez MA, et al: An enhanced international prognostic index
(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated
in the rituximab era. Blood. 123:837–842. 2014. View Article : Google Scholar
|
|
16
|
Kwon SH, Kang DR, Kim J, Yoon JK, Lee SJ,
Jeong SH, Lee HW and An YS: Prognostic value of negative interim
2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large
B-cell lymphoma. Clin Radiol. 71:280–286. 2016. View Article : Google Scholar
|
|
17
|
Parvez A, Tau N, Hussey D, Maganti M and
Metser U: 18F-FDG PET/CT metabolic tumor parameters and
radiomics features in aggressive non-Hodgkins lymphoma as
predictors of treatment outcome and survival. Ann Nucl Med.
32:410–416. 2018. View Article : Google Scholar
|
|
18
|
Kim TM, Paeng JC, Chun IK, Keam B, Jeon
YK, Lee SH, Kim DW, Lee DS, Kim CW, Chung JK, et al: Total lesion
glycolysis in positron emission tomography is a better predictor of
outcome than the international prognostic index for patients with
diffuse large B cell lymphoma. Cancer. 119:1195–1202. 2013.
View Article : Google Scholar
|
|
19
|
Esfahani SA, Heidari P, Halpern EF,
Hochberg EP, Palmer EL and Mahmood U: Baseline total lesion
glycolysis measured with 18F-FDG PET/CT as a predictor
of progression-free survival in diffuse large B-cell lymphoma: A
pilot study. Am J Nucl Med Mol Imaging. 3:272–281. 2013.
|
|
20
|
Song MK, Chung JS, Shin HJ, Lee SM, Lee
SE, Lee HS, Lee GW, Kim SJ, Lee SM and Chung DS: Clinical
significance of metabolic tumor volume by PET/CT in stages II and
III of diffuse large B cell lymphoma without extranodal site
involvement. Ann Hematol. 91:697–703. 2012. View Article : Google Scholar
|
|
21
|
Tatsumi M, Isohashi K, Matsunaga K, Watabe
T, Kato H, Kanakura Y and Hatazawa J: Volumetric and texture
analysis on FDG PET in evaluating and predicting treatment response
and recurrence after chemotherapy in follicular lymphoma. Int J
Clin Oncol. 24:1292–1300. 2019. View Article : Google Scholar
|
|
22
|
Gallicchio R, Mansueto G, Simeon V,
Nardelli A, Guariglia R, Capacchione D, Soscia E, Pedicini P,
Gattozzi D, Musto P and Storto G: F-18 FDG PET/CT quantization
parameters as predictors of outcome in patients with diffuse large
B-cell lymphoma. Eur J Haematol. 92:382–389. 2014. View Article : Google Scholar
|
|
23
|
Adams HJ, de Klerk JM, Fijnheer R,
Heggelman BG, Dubois SV, Nievelstein RA and Kwee TC: Prognostic
superiority of the national comprehensive cancer network
international prognostic index over pretreatment whole-body
volumetric-metabolic FDG PET/CT metrics in diffuse large B-cell
lymphoma. Eur J Haematol. 94:532–539. 2015. View Article : Google Scholar
|
|
24
|
Xie M, Zhai W, Cheng S, Zhang H, Xie Y and
He W: Predictive value of F-18 FDG PET/CT quantization parameters
for progression-free survival in patients with diffuse large B-cell
lymphoma. Hematology. 21:99–105. 2016. View Article : Google Scholar
|
|
25
|
Manohar K, Mittal BR, Bhattacharya A,
Malhotra P and Varma S: Prognostic value of quantitative parameters
derived on initial staging 18F-fluorodeoxyglucose positron emission
tomography/computed tomography in patients with high-grade
non-Hodgkins lymphoma. Nucl Med Commun. 33:974–981. 2012.
View Article : Google Scholar
|
|
26
|
Fuertes S, Setoain X, Lopez-Guillermo A,
Carrasco JL, Rodríguez S, Rovira J and Pons F: Interim FDG PET/CT
as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl
Med Mol Imaging. 40:496–504. 2013. View Article : Google Scholar
|
|
27
|
Wu X, Pertovaara H, Korkola P, Vornanen M,
Järvenpää R, Dastidar P, Eskola H and Kellokumpu-Lehtinen PL: Early
interim PET/CT predicts post-treatment response in diffuse large
B-cell lymphoma. Acta Oncol. 53:1093–1099. 2014. View Article : Google Scholar
|
|
28
|
Oñate-Ocaña LF, Cortés V, Castillo-Llanos
R, Terrazas A, Garcia-Perez O, Pitalúa-Cortes Q, Ponce M,
Dueñas-Gonzalez A and Candelaria M: Metabolic tumor volume changes
assessed by interval 18fluorodeoxyglucose positron
emission tomography-computed tomography for the prediction of
complete response and survival in patients with diffuse large
B-cell lymphoma. Oncol Lett. 16:1411–1418. 2018.
|
|
29
|
Tateishi U, Tatsumi M, Terauchi T, Ando K,
Niitsu N, Kim WS, Suh C, Ogura M and Tobinai K: Prognostic
significance of metabolic tumor burden by positron emission
tomography/computed tomography in patients with relapsed/refractory
diffuse large B-cell lymphoma. Cancer Sci. 106:186–193. 2015.
View Article : Google Scholar
|
|
30
|
Petrich AM, Gandhi M, Jovanovic B,
Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F,
Hernandez-Ilizaliturri FJ, et al: Impact of induction regimen and
stem cell transplantation on outcomes in double-hit lymphoma: A
multicenter retrospective analysis. Blood. 124:2354–2361. 2014.
View Article : Google Scholar
|
|
31
|
Huntington SF, Nasta SD, Schuster SJ,
Doshi JA and Svoboda J: Utility of interim and end-of-treatment
[18F]-fluorodeoxyglucose positron emission
tomography-computed tomography in front line therapy of patients
with diffuse large B-cell lymphoma. Leuk Lymphoma. 56:2579–2584.
2015. View Article : Google Scholar
|
|
32
|
Pregno P, Chiappela A, Bellò M, Botto B,
Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga
M, et al: Interim 18-FDG-PET/CT failed to predict the outcome in
diffuse large B-cell lymphoma patients treated at the diagnosis
with rituximab-CHOP. Blood. 119:2066–2073. 2012. View Article : Google Scholar
|
|
33
|
Adams HJ and Kwee TC: Prognostic value of
interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma:
Systematic review and meta-analysis. Crit Rev Oncol Hematol.
106:55–63. 2016. View Article : Google Scholar
|
|
34
|
Jiang SY, Qin Y, Liu P, Yang J, Yang S, He
X, Zhou S, Gui L, Zhang C, Zhou L, et al: A prognostic nomogram
constructed for relapsed or refractory diffuse large B-cell
lymphoma patients. Asia Pac J Clin Oncol. July 1–2019.(Online ahead
of print). simplehttps://doi.org/10.1111/ajco.13222 View Article : Google Scholar
|
